Consenso da Sociedade Brasileira de Reumatologia para o diagnóstico, manejo e tratamento da nefrite lúpica

Bernatsky, 2006, Mortality in systemic lupus erythematosus, Arthritis Rheum., 54, 2550, 10.1002/art.21955 Souza, 2012, Mortality profile related to systemic lupus erythematosus: a multiple cause‐of‐death analysis, Journal of Rheumatology, 39, 496, 10.3899/jrheum.110241 Telles, 2013, Causes and predictors of death in Brazilian lupus patients, Rheumatol Int., 33, 467, 10.1007/s00296-012-2372-x Beck, 2009, Treatment of membranous lupus nephritis: where are we now?, J Am Soc Nephrol., 20, 690, 10.1681/ASN.2009020216 Kang, 2011, The causes of death in Korean patients with systemic lupus erythematosus over 11 years, Lupus, 20, 989, 10.1177/0961203311402245 Yap, 2012, Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome, Nephrology, 17, 352, 10.1111/j.1440-1797.2012.01574.x Houssiau, 2010, The 10‐year follow‐up data of the Euro‐Lupus Nephritis Trial comparing low‐dose and high‐dose intravenous cyclophosphamide, Ann Rheum Dis., 69, 61, 10.1136/ard.2008.102533 Rabbani, 2009, Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients, Lupus, 18, 848, 10.1177/0961203309103410 Ribeiro, 2013, Survival of lupus patients on dialysis: a Brazilian cohort, Rheumatol., 52, 494, 10.1093/rheumatology/kes298 Dooley, 2007, Clinical and laboratory features of lupus nephritis Nived, 2013, An observational study of outcome in SLE patients with biopsy‐verified glomerulonephritis between 1986 and 2004 in a defined area of Southern Sweden: the clinical utility of the ACR renal response criteria and predictors for renal outcome, Scand J Rheumatol., 42, 383, 10.3109/03009742.2013.799224 Markowitz, 2009, Classification of lupus nephritis, Curr Opin Nephrol Hypertens, 18, 220, 10.1097/MNH.0b013e328327b379 Bomback, 2010, Updates on the treatment of lupus nephritis, J Am Soc Nephrol., 21, 2028, 10.1681/ASN.2010050472 Hergessel, 1998, Safety of ultrasound‐guided percutaneous renal biopsy‐retrospective analysis of 1090 consecutive cases, Nephrol Dial Transplant, 13, 975, 10.1093/ndt/13.4.975 Zhang, 2012, A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies, Kidney Int., 81, 401, 10.1038/ki.2011.354 Mok, 2006, Long‐term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide, Am J Med., 119, 355, 10.1016/j.amjmed.2005.08.045 Troyanov, 2004, Idiopathic membranous nephropathy: definition and relevance of a partial remission, Kidney International, 66, 1199, 10.1111/j.1523-1755.2004.00873.x Chen, 2008, Value of a complete or partial remission in severe lupus nephritis, Clin J Am Soc Nephrol., 3, 46, 10.2215/CJN.03280807 Moore, 2006, Systematic review and meta‐analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis, Arthritis Res Ther., 8, R182, 10.1186/ar2093 Hahn, 2012, American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care Res., 64, 797, 10.1002/acr.21664 Bertsias, 2012, Joint European League Against Rheumatism and European Renal Association‐European Dialysis and Transplant Association (Eular/ERA‐EDTA) recommendations for the management of adult and paediatric lupus nephritis, Ann Rheum Dis., 71, 1771, 10.1136/annrheumdis-2012-201940 Giannico, 2013, Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?, Clin J Am Soc Nephrol., 8, 138, 10.2215/CJN.03400412 Grande, 1998, Renal biopsy in lupus nephritis, Lupus, 7, 611, 10.1191/096120398678920730 Weening, 2004, The classification of glomerulonephritis in systemic lupus erythematosus revisited, J Am Soc Nephrol., 15, 241, 10.1097/01.ASN.0000108969.21691.5D Weening, 2004, The classification of glomerulonephritis in systemic lupus erythematosus revisited, Kidney Int., 65, 521, 10.1111/j.1523-1755.2004.00443.x Daleboudt, 2009, The clinical relevance of a repeat biopsy in lupus nephritis flares, Nephrol Dial Transplant, 24, 3712, 10.1093/ndt/gfp359 Sidiropoulos, 2005, Lupus nephritis flares, Lupus, 14, 49, 10.1191/0961203305lu2059oa Arends, 2012, Long‐term follow‐up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis, Ann Rheum Dis., 71, 966, 10.1136/annrheumdis-2011-200384 Mok, 2012, Understanding lupus nephritis: diagnosis, management, and treatment options, Int J Womens Health, 4, 213, 10.2147/IJWH.S28034 Saxena, 2011, Lupus nephritis: current update, Arthritis Res Ther., 13, 240, 10.1186/ar3378 Cameron, 1999, Lupus nephritis, J Am Soc Nephrol., 10, 413, 10.1681/ASN.V102413 Korbet, 2000, Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group, Am J Kidney Dis., 35, 904, 10.1016/S0272-6386(00)70262-9 Contreras, 2005, Factors associated with poor outcomes in patients with lupus nephritis, Lupus, 14, 890, 10.1191/0961203305lu2238oa Tektonidou, 2004, Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long‐term outcome, Arthritis Rheum., 50, 2569, 10.1002/art.20433 Brunner, 2012, Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis, Arthritis Rheum., 64, 2687, 10.1002/art.34426 Do Nascimento, 2006, Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis, Arthritis Rheum., 54, 1568, 10.1002/art.21875 De Macedo, 2011, Antibodies to ribosomal P proteins in lupus nephritis: a surrogate marker for a better renal survival?, Autoimmun Rev., 10, 126, 10.1016/j.autrev.2010.09.002 2006, The American College of Rheumatology Response Criteria for Proliferative and Membranous Renal Disease in Systemic Lupus Erythematosus Clinical Trials, Arthritis Rheum., 54, 421, 10.1002/art.21625 Navarra, 2010, Infections in systemic lupus erythematosus, Lupus, 19, 1419, 10.1177/0961203310374486 Zandman-Goddard, 2005, Infections and systemic lupus erythematosus, Autoimmunity, 38, 473, 10.1080/08916930500285352 Ribeiro, 2010, Can lupus flares be associated with tuberculosis infection?, Clin Rev Allergy Immunol., 38, 163, 10.1007/s12016-009-8149-7 Sciascia, 2013, Management of infection in systemic lupus erythematosus, Best Practice & Research Clinical Rheumatology, 27, 377, 10.1016/j.berh.2013.07.002 Ruiz-Irastorza, 2009, Predictors of major infections in systemic lupus erythematosus, Arthritis Res Ther., 11, R109, 10.1186/ar2764 Van Assen, 2011, EULAR Recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis., 70, 414, 10.1136/ard.2010.137216 Abu-Shakra, 2009, Safety of vaccination of patients with systemic lupus erythematosus, Lupus, 18, 1205, 10.1177/0961203309346507 Campos, 2013, High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus, Arthritis Care Res. (Hoboken), 65, 1121, 10.1002/acr.21948 Silva, 2013, Vaccinations in juvenile chronic inflammatory diseases: an update, Nat Rev Rheumatol., 9, 532, 10.1038/nrrheum.2013.95 Elkayam, 2002, Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis and systemic lupus erythematosus, Clinical Infectious Diseases, 34, 147, 10.1086/338043 Abu-Shakra, 2002, Specific antibody response after influenza immunization in systemic lupus erythematosus, J Rheumatol, 29, 2555 Gaitonde, 2002, Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment, Ann Rheum Dis., 61, 251, 10.1136/ard.61.3.251 Gupta, 2008, Prophylatic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of U.S. rheumatologists and review of literature, J Clin Rheumatol., 14, 267, 10.1097/RHU.0b013e31817a7e30 Austin, 1986, Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs, N Engl J Med., 314, 614, 10.1056/NEJM198603063141004 Illei, 2001, Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long‐term renal outcome without adding toxicity in patients with lupus nephritis, Ann Intern Med., 135, 248, 10.7326/0003-4819-135-4-200108210-00009 Boumpas, 1993, Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy, Ann Intern Med., 119, 366, 10.7326/0003-4819-119-5-199309010-00003 Appel, 2009, Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis, J Am Soc Nephrol., 20, 1103, 10.1681/ASN.2008101028 Ginzler, 2005, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, N Engl J Med., 353, 2219, 10.1056/NEJMoa043731 Ong LM1, 2005, Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis, Nephrology (Carlton), 10, 504, 10.1111/j.1440-1797.2005.00444.x Mak, 2009, Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta‐analysis and meta‐regression, Rheumatology (Oxford), 48, 944, 10.1093/rheumatology/kep120 Touma, 2011, Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis, J Rheumatol., 38, 69, 10.3899/jrheum.100130 Liu, 2012, Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta‐analysis of randomized controlled trials, Drugs, 72, 1521, 10.2165/11635030-000000000-00000 Houssiau, 2004, Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long‐term follow‐up of patients in the Euro‐Lupus Nephritis Trial, Arthritis Rheum., 50, 3934, 10.1002/art.20666 Lee, 2010, Induction and maintenance therapy for lupus nephritis: a systematic review and meta‐analysis, Lupus, 19, 703, 10.1177/0961203309357763 McKinley, 2009, Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option, Clin J Am Soc Nephrol., 4, 1754, 10.2215/CJN.02670409 Mok, 2001, Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide‐containing regimens, Am J Kidney Dis., 38, 256, 10.1053/ajkd.2001.26084 Yee, 2004, Eular randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis, Ann Rheum Dis., 63, 525, 10.1136/ard.2002.003574 Isenberg, 2010, Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study, Rheumatology (Oxford), 49, 128, 10.1093/rheumatology/kep346 Walsh, 2013, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study, Am J Kidney Dis., 61, 710, 10.1053/j.ajkd.2012.11.042 Boumpas, 1992, Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis, Lancet, 340, 741, 10.1016/0140-6736(92)92292-N Grootscholten, 2007, A prospective study of anti‐chromatin and anti‐C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone, Ann Rheum Dis., 66, 693, 10.1136/ard.2006.065425 Houssiau, 2002, Immunosuppressive therapy in lupus nephritis. The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide, Arthritis Rheum., 46, 2121, 10.1002/art.10461 Dooley, 2011, Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis, N England J Med., 365, 1886, 10.1056/NEJMoa1014460 Houssiau, 2010, Azathioprine versus mycophenolate mofetil for long‐term immunosuppression in lupus nephritis: results from the Maintain Nephritis Trial, Ann Rheum Dis., 69, 2083, 10.1136/ard.2010.131995 Moroni, 2006, Withdrawal of therapy in patients with proliferative lúpus nephritis: long‐term follow‐up, Nephrology Dialysis Transplantation, 21, 1541, 10.1093/ndt/gfk073 Houssiau, 2013, Current management of lupus nephritis, Best Pract Res Clin Rheumatol., 27, 319, 10.1016/j.berh.2013.07.004 Boumpas, 2010, A decade of mycophenolate mofetil for lupus nephritis: is the glass half‐empty or half‐full?, Ann Rheum Dis., 69, 2059, 10.1136/ard.2010.139683 Huong, 1999, Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center, Medicine, 78, 148, 10.1097/00005792-199905000-00002 Ponticelli, 1998, Renal biopsy in lupus nephritis‐what for, when and how often?, Nephrol Dial Transplant., 13, 2452, 10.1093/ndt/13.10.2452 Zabaleta-Lanz, 2003, Silent nephritis in systemic lupus erythematosus, Lupus, 12, 26, 10.1191/0961203303lu259oa Chan, 1999, Treatment of membranous lupus nephritis with nephritic syndrome by sequential immunosuppression, Lupus, 8, 545, 10.1191/096120399678840837 Mok, 2009, Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma, Nat Rev Nephrol., 5, 212, 10.1038/nrneph.2009.14 Chen, 2013, A glimpse of the glomerular milieu: From endothelial cell to thrombotic disease in nephrotic syndrome, Microvasc Res., 89, 1, 10.1016/j.mvr.2013.06.011 Austin, 2005, Membranous lupus nephritis, Lupus, 14, 65, 10.1191/0961203305lu2062oa Mok, 2004, Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open‐label trial, Am J Kidney Dis., 43, 269, 10.1053/j.ajkd.2003.10.029 Hallegua, 2000, Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9, 241, 10.1191/096120300680198935 Austin, 2009, Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy, J Am Soc Nephrol., 20, 901, 10.1681/ASN.2008060665 Radhakrishnan, 2010, Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis, Kidney Int., 77, 152, 10.1038/ki.2009.412 Kasitanon, 2006, Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis, Lupus, 15, 366, 10.1191/0961203306lu2313oa Gourley, 1996, Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial, Ann Intern Med., 125, 549, 10.7326/0003-4819-125-7-199610010-00003 Erre, 2014, Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study, Rheumatol Int., 34, 535, 10.1007/s00296-013-2900-3 Pons-Estel, 2014, Renal involvement in antiphospholipid syndrome, Curr Rheumatol Rep., 16, 397, 10.1007/s11926-013-0397-0 Galindo, 2009, Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti‐phospholipid antibodies, Rheumatology (Oxford), 48, 1003, 10.1093/rheumatology/kep152 Shen, 2008, IgA antiphospholipid antibodies are an independent risk factor for thromboses, Lupus, 17, 996, 10.1177/0961203308093460 Zheng, 2009, Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases, Arthritis Res Ther., 11, R93, 10.1186/ar2736 Silvarino, 2011, Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus, Lupus, 20, 721, 10.1177/0961203310397410 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost., 4, 295, 10.1111/j.1538-7836.2006.01753.x Cervera, 2011, Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non‐criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions, Lupus, 20, 165, 10.1177/0961203310395051 D’Cruz, 2009, Renal manifestations of the antiphospholipid syndrome, Curr Rheumatol Rep., 11, 52, 10.1007/s11926-009-0008-2 Ruiz-Irastorza, 2011, Evidence‐based recommendations for the prevention and long‐term management of thrombosis in antiphospholipid antibody‐positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, 20, 206, 10.1177/0961203310395803 Danowski, 2013, Guidelines for the treatment of antiphospholipid syndrome, Rev Bras Reumatol., 53, 184, 10.1590/S0482-50042013000200005 Belmont, 2013, Treatment of systemic lupus erythematosus – 2013 update, Bull. Hosp Jt Dis., 71, 208 Schur, 2014, Overview of the therapy and prognosis of systemic lupus erythematosus in adults Petri, 2013, Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein‐to‐creatinine ratio, Arthritis Rheum., 65, 1865, 10.1002/art.37953 Ruiz-Irastorza, 2010, Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage, Arthritis Care Res (Hoboken), 62, 1160, 10.1002/acr.20186 Praga, 2002, Slowing the progression of renal failure, Kidney Int Suppl., 80, 18, 10.1046/j.1523-1755.61.s80.5.x Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. http://www.uptodate.com/contents/. Accessado em 7 de abril de 2014. Mann, 2011, What's new in hypertension 2010?, Nephrol Dial Transplant., 26, 50, 10.1093/ndt/gfq776 Durán-Barragán, 2008, Rheumatology (Oxford), 47, 1093, 10.1093/rheumatology/ken208 Kanda, 2005, Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy, Lupus, 14, 288, 10.1191/0961203305lu2076oa Tse, 2005, Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria, Lupus, 14, 947, 10.1191/0961203305lu2249oa Susantitaphong, 2013, Efficacy and safety of combined vs. single renin‐angiotensin‐aldosterone system blockade in chronic kidney disease: a meta‐analysis, Am J Hypertens., 26, 424, 10.1093/ajh/hps038 Fessler, 2005, Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual, Arthritis Rheum., 52, 1473, 10.1002/art.21039 Pons-Estel, 2009, Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort, Arthritis Rheum., 61, 830, 10.1002/art.24538 Tsakonas, 1998, A long‐term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group, Lupus, 7, 80, 10.1191/096120398678919778 Ruiz-Irastorza, 2010, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Ann Rheum Dis., 69, 20, 10.1136/ard.2008.101766 Marmor, 2011, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy, Ophthalmology, 118, 415, 10.1016/j.ophtha.2010.11.017 Culwell, 2009, Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review, Obstet Gynecol., 114, 341, 10.1097/AOG.0b013e3181ae9c64 Buyon, 2005, The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial, Ann Intern Med., 142, 953, 10.7326/0003-4819-142-12_Part_1-200506210-00004 Petri, 2011, Lupus Atherosclerosis Prevention Study (Laps), Ann Rheum Dis., 70, 760, 10.1136/ard.2010.136762 Plazak, 2011, Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double‐masked, placebo‐controlled study, Arthritis Res Ther., 13, R117, 10.1186/ar3402 Berden, 1997, Lupus nephritis, Kidney Int., 52, 538, 10.1038/ki.1997.365 Ginzler EM1, 1988, Outcome and prognosis in systemic lupus erythematosus, Rheum Dis Clin North Am., 14, 67, 10.1016/S0889-857X(21)00947-9 Clark, 1998, Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease, Lupus, 7, 649, 10.1191/096120398678920802 Najafi, 2001, Significance of histologic patterns of glomerular injury upon long‐term prognosis in severe lupus glomerulonephritis, Kidney Int., 59, 2156, 10.1046/j.1523-1755.2001.00730.x Hill, 2001, Proteinuria and tubulointerstitial lesions in lupus nephritis, Kidney Int., 60, 1893, 10.1046/j.1523-1755.2001.00017.x Hill, 2002, Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy, Kidney Int., 61, 2176, 10.1046/j.1523-1755.2002.00357.x Daugas, 2002, J Am Soc Nephrol., 13, 42, 10.1681/ASN.V13142 Tektonidou, 2009, Renal involvement in the antiphospholipid syndrome (APS)‐APS nephropathy, Clin Rev Allergy Immunol., 36, 131, 10.1007/s12016-008-8112-z Sciascia, 2014, Renal involvement in antiphospholipid syndrome, Nature Rev Nephrol., 10, 279, 10.1038/nrneph.2014.38 Illei, 2001, Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long‐term renal outcome without adding toxicity in patients with lupus nephritis, Ann Intern Med., 135, 248, 10.7326/0003-4819-135-4-200108210-00009 Oliveira-Santos, 2011, Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil, Lupus, 20, 320, 10.1177/0961203310383736 Pagni, 2013, The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients, Nephrol Dial Transplant., 28, 3014, 10.1093/ndt/gft272 Leandro, 2005, B‐cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients, Rheumatology, 44, 1542, 10.1093/rheumatology/kei080 Lu, 2009, A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London: the first fifty patients, Arthritis Rheum., 15, 482, 10.1002/art.24341 Rovin, 2012, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study, Arthritis Rheum., 64, 1215, 10.1002/art.34359 Zavada, 2010, Cyclosporine or intravenous cyclophosphamide for lupus nephritis: the Cyclofa‐Lune study, Lupus, 19, 1281, 10.1177/0961203310371155 Chen, 2011, Short‐term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial, Am J Kidney Dis., 57, 235, 10.1053/j.ajkd.2010.08.036 Chen, 2012, Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial, Lupus, 21, 944, 10.1177/0961203312442259 Wang, 2012, Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non‐randomized prospective cohort study, Lupus, 21, 1025, 10.1177/0961203312448105 Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo‐controlled, phase 3 trial, Lancet, 26, 721, 10.1016/S0140-6736(10)61354-2 Furie, 2011, A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum., 63, 3918, 10.1002/art.30613 Dooley, 2013, Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE, Lupus, 22, 63, 10.1177/0961203312465781 Faco, 2007, Risk factors associated with the death of patients hospitalized for juvenile systemic lupus erythematosus, Braz J Med Biol Res., 40, 993, 10.1590/S0100-879X2006005000110 Silva, 2012, Taxonomy for systemic lupus erythematosus with onset before adulthood, Arthritis Care Res. (Hoboken), 64, 1787, 10.1002/acr.21757 Tucker, 1995, Adult and childhood‐onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome, Br J Rheumatol., 34, 866, 10.1093/rheumatology/34.9.866 Costallat, 1994, Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset, Clin Exp Rheumatol., 12, 603 Araujo, 2012, Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus, Lupus, 21, 872, 10.1177/0961203312441047 Barsalou, 2013, An update on childhood‐onset systemic lupus erythematosus, Curr Opin Rheumatol., 25, 616, 10.1097/BOR.0b013e328363e868 Brunner, 2006, Cost of treatment of childhood‐onset systemic lupus erythematosus, Arthritis Rheum., 55, 184, 10.1002/art.21845 Mina, 2012, Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus, Arthritis Care Res. (Hoboken), 64, 375, 10.1002/acr.21558 Bennett, 2013, Biomarkers and updates on pediatrics lupus nephritis, Rheum Dis Clin North Am., 39, 833, 10.1016/j.rdc.2013.05.001 Sundel, 2012, Aspreva Lupus Management Study (ALMS) Group.Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two‐phase, prospective randomized trial, Lupus, 21, 1433, 10.1177/0961203312458466 Aikawa, 2012, Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy, Clin Exp Rheumatol., 30, 445 Swan, 2011, Systematic review and meta‐analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis, J Investig Med., 59, 246, 10.2310/JIM.0b013e318204c965 Terrier, 2010, Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry, Arthritis Rheum., 62, 2458, 10.1002/art.27541 Shafi, 2007, Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis, J Vasc Access, 8, 103, 10.1177/112972980700800207 Cheigh, 1993, End‐stage renal disease in systemic lupus erythematosus, Am J Kid Dis., 21, 2, 10.1016/S0272-6386(12)80712-8 Nissenson, 1990, Outcome of end‐stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders, Q J Med., 74, 63 Pollock, 1987, Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus. The Australian and New Zealand experience, Aust N Z J Med., 17, 321, 10.1111/j.1445-5994.1987.tb01236.x Szeto, 1998, Factors associated with active systemic lupus erythematosus after endstage renal disease, J Rheumatol., 25, 1520 Bruce, 1999, Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy, J Rheumatol., 26, 1490 Okano, 2001, Analysis of lupus activity in end‐stage renal disease treated by hemodialysis, Intern Med., 40, 598, 10.2169/internalmedicine.40.598 Krane, 1999, Persistent lupus activity in end‐stage renal disease, Am J Kidney Dis., 33, 872, 10.1016/S0272-6386(99)70419-1 Ribeiro, 2005, Activity of systemic lupus erythematosus in end‐stage renal disease patients: study in a Brazilian cohort, Am J Nephrol., 25, 596, 10.1159/000089708 Nossent, 1990, Systemic lupus erythematosus: analysis of disease activity in 55 patients with end‐stage renal failure treated with hemodialysis or continous ambulatory peritoneal dialysis. Dutch Working Party on SLE, Am J Med., 89, 169, 10.1016/0002-9343(90)90295-O Jarrett, 1983, The clinical course of end‐stage renal disease in systemic lupus erythematosus, Arch Intern Med., 143, 1353, 10.1001/archinte.1983.00350070073014 Coplon, 1983, The long‐term clinical course of systemic lupus erythematosus in end‐stage renal disease, N Engl J Med., 308, 186, 10.1056/NEJM198301273080403 Cheigh, 1990, Systemic lupus erythematosus in patients with end‐stage renal disease: long‐term follow‐up on the prognosis of patients and the evolution of lupus activity, Am J Kidney Dis., 16, 189, 10.1016/S0272-6386(12)81017-1 Uramoto, 1999, Trends in the incidence and mortality of systemic lupus erythematosus, 1950‐1992, Arthritis Rheum., 42, 46, 10.1002/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2 Ziff, 1983, Dialysis and transplantation in end‐stage lupus nephritis, N Engl J Med., 308, 218, 10.1056/NEJM198301273080411 Rodby, 1987, Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis, Am J Med., 83, 613, 10.1016/0002-9343(87)90888-6 Lee, 2003, Poor prognosis of end‐stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients, Lupus, 12, 827, 10.1191/0961203303lu474oa Goo, 2004, The evolution of lupus activity among patients with end‐stage renal disease secondary to lupus nephritis, Yonsei Med J., 45, 199, 10.3349/ymj.2004.45.2.199 Grimbert, 1998, Long‐term outcome of kidney transplantation in patients with systemic lupus erythematosus: a multicenter study. Groupe Cooperatif de Transplantation d’île de France, Transplantation, 66, 1000, 10.1097/00007890-199810270-00006 Ward, 2000, Outcomes of renal transplantation among patients with end‐stage renal disease caused by lupus nephritis, Kidney Int., 57, 2136, 10.1046/j.1523-1755.2000.00065.x Oliveira, 2012, Renal transplantation in lupus nephritis: a Brazilian cohort, Lupus, 21, 570, 10.1177/0961203311430220 Moroni, 2005, The long‐term prognosis of renal transplantation in patients with lupus nephritis, Am J Kidney Dis., 45, 903, 10.1053/j.ajkd.2005.01.038 Stone, 1999, Antiphospholipid syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus, Am J Kidney Dis., 34, 1040, 10.1016/S0272-6386(99)70009-0 Bunnapradist, 2006, Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procedure and Transplantation Network database, Transplantation, 82, 612, 10.1097/01.tp.0000235740.56573.c6 Hickman, 2011, Causes and management of infertility in systemic lupus erythematosus, Rheumatology, 50, 1551, 10.1093/rheumatology/ker105 Huong, 2002, Risk of Ovarian Failure and Fertility After Intravenous Cyclophosphamide. A Study in 84 Patients, J Rheumatol., 29, 2571 Carmona, 1999, Obstetrical outcome of pregnancy in patients with systemic Lupus erythematosus. A study of 60 cases, Eur J Obstet Gynecol Reprod Biol., 83, 137, 10.1016/S0301-2115(98)00312-1 Cortés-Hernández, 2002, Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies, Rheumatology (Oxford), 41, 643, 10.1093/rheumatology/41.6.643 Lima, 1995, Obstetric outcome in systemic lupus erythematosus, Semin Arthritis Rheum., 25, 184, 10.1016/S0049-0172(95)80030-1 Witter, 2007, Management of the high‐risk lupus pregnant patient, Rheum Dis Clin North Am., 33, 253, 10.1016/j.rdc.2007.02.002 Buyon, 2009, Updates on lupus and pregnancy, Bull NYU Hosp Jt Dis., 67, 271 Clowse, 2007, Lupus activity in pregnancy, Rheum Dis Clin North Am., 33, 237, 10.1016/j.rdc.2007.01.002 Baer, 2011, Lupus and pregnancy, Obstet Gynecol Suv., 66, 639, 10.1097/OGX.0b013e318239e1ee Clowse, 2008, A national study of the complications of lupus in pregnancy, Am J Obstet Gynecol., 199, 127, 10.1016/j.ajog.2008.03.012 Yuen, 2008, Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: results from a case control study and literature review, Open Rheumatol J., 2, 89, 10.2174/1874312900802010089 Clark, 2005, Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40‐year period, J Rheumatol., 32, 1709 Chakravarty, 2005, Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus, Am J Obstet Gynecol., 192, 1897, 10.1016/j.ajog.2005.02.063 Clowse, 2006, Hydroxychloroquine in lupus pregnancy, Arthritis Rheum., 54, 3640, 10.1002/art.22159 Smyth, 2010, A systematic review and meta‐analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis, Clin J Am Soc Nephrol., 5, 2060, 10.2215/CJN.00240110 Moroni, 2003, The risk of pregnancy in patients with lupus nephritis, J Nephrol., 16, 161 Qazi, 2006, Autoantibodies, low complement, and obesity predict preeclampsia in SLE: a case‐control study, Arthritis Rheum., 54, S264 Lateef, 2012, Management of pregnancy in systemic lupus erythematosus, Nat Rev Rheumatol., 8, 710, 10.1038/nrrheum.2012.133 Verghese, 2012, Antenatal screening for pre‐eclampsia: evaluation of the NICE and pre‐eclampsia community guidelines, J Gynecol Obstet., 32, 128, 10.3109/01443615.2011.635224 Imbasciati, 2009, Pregnancy in women with pre‐existing lupus nephritis: predictors of fetal and maternal outcome, Nephrol Dial Transplant., 24, 519, 10.1093/ndt/gfn348 Klumb, 2005, Impacto da nefrite sobre os resultados gestacionais de mulheres com lúpus eritematoso sistêmico, Rev Bras Reumatol., 45, 107, 10.1590/S0482-50042005000300004 Ritchie, 2012, Maternal deaths in women with lupus nephritis: a review of published evidence, Lupus, 21, 534, 10.1177/0961203311434939 Østensen, 2006, Anti‐inflammatory and immunosuppressive drugs and reproduction, Arthritis Res Ther., 8, 209, 10.1186/ar1957 Bertsias, 2008, Eular recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the Eular Standing Committee for International Clinical Studies Including Therapeutics, Ann Rheum Dis., 67, 195, 10.1136/ard.2007.070367 Stojan, 2012, Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management, Expert Rev Clin Immunol., 8, 439, 10.1586/eci.12.36 Petri, 2007, The Hopkins Lupus Pregnancy Center: ten key issues in management, Rheum Dis Clin North Am., 33, 27, 10.1016/j.rdc.2007.01.003 Diniz-da-Costa, 2012, Systemic lupus erythematosus and pregnancy, Acta Med Port., 25, 448